Soluble ST2, often written as sST2, is a blood marker linked with heart strain, inflammation, fibrosis, and worsening heart failure risk. It does not diagnose a heart attack the way troponin can, and it does not replace BNP or NT-proBNP for evaluating shortness of breath. Its main strength is prognosis: sST2 can help estimate whether someone with known or suspected heart failure has a higher risk of hospitalization, disease progression, or death over time.
A high sST2 result usually means the heart and blood vessels are under biological stress, especially when the result is above commonly used cut points such as 35 ng/mL. The number becomes most useful when interpreted with symptoms, exam findings, echocardiogram results, kidney function, BNP or NT-proBNP, troponin, and the person’s treatment plan. Because sST2 can rise in several inflammatory and cardiovascular conditions, it should guide follow-up rather than stand alone as a diagnosis.
- sST2 measures a soluble form of the ST2 receptor, a marker linked with cardiac stress, inflammation, fibrosis, and ventricular remodeling.
- A high sST2 result is most often used to estimate prognosis in heart failure, not to diagnose heart failure by itself.
- Many clinical studies and assays use 35 ng/mL as a risk cut point; values above this level are generally associated with higher risk.
- sST2 usually does not require fasting and is measured from a standard blood sample.
- sST2 can add information to BNP or NT-proBNP because it reflects a different biological pathway.
- Urgent care is needed for chest pain, severe shortness of breath, fainting, blue lips, confusion, or rapidly worsening swelling, regardless of the sST2 number.
Table of Contents
- What the sST2 Blood Test Measures
- When the sST2 Test Is Ordered
- Normal Range, High sST2, and Result Patterns
- High sST2 and Heart Failure Risk
- How sST2 Fits With BNP, NT-proBNP, Troponin, and Galectin-3
- Non-Heart Causes and Result Confounders
- What to Do After a High sST2 Result
- Limits of the Test and Common Misunderstandings
What the sST2 Blood Test Measures
The sST2 blood test measures soluble ST2, a circulating form of a receptor involved in inflammation and tissue repair. ST2 is part of the interleukin-1 receptor family. The gene behind it is often called IL1RL1. In the heart, the ST2 system is closely tied to mechanical stretch, inflammation, fibrosis, and remodeling.
There are two clinically important forms of ST2. One form is membrane-bound ST2L, which sits on cells and can bind interleukin-33, also called IL-33. This IL-33/ST2L pathway appears to have protective effects in the heart under stress. The other form is soluble ST2, or sST2, which floats in the blood. When sST2 rises, it can act like a “decoy” receptor by binding IL-33 and reducing its protective signaling.
In simple terms, a higher sST2 level suggests that the heart and vascular system may be responding to strain, inflammation, and scarring signals. This is why sST2 is often discussed as a marker of myocardial stress and fibrosis rather than a marker of acute cell death.
That distinction matters. Troponin rises when heart muscle cells are injured. BNP and NT-proBNP rise mainly when the heart chambers are stretched by pressure or volume. sST2 reflects a related but different process: the stress-and-remodeling pathway that can contribute to a stiffer, weaker, or more vulnerable heart over time.
sST2 is not a routine screening test for everyone. It is usually considered when a clinician is already evaluating known heart failure, possible worsening heart failure, or overall cardiovascular risk in a higher-risk setting.
When the sST2 Test Is Ordered
Clinicians may order sST2 when they want more information about risk in a person with heart failure or suspected cardiac stress. It is most often used as an add-on test rather than the first test ordered.
Common situations include:
- Known chronic heart failure, especially when estimating future risk
- Recent hospitalization or emergency evaluation for worsening heart failure
- Shortness of breath where heart failure is being considered along with other causes
- Follow-up after treatment changes, when a clinician wants to track risk over time
- Research or specialty cardiology settings where several cardiac biomarkers are compared
The test can be used in people with heart failure with reduced ejection fraction, mildly reduced ejection fraction, or preserved ejection fraction. Ejection fraction describes how much blood the left ventricle pumps out with each beat. A normal ejection fraction does not rule out heart failure, because heart failure can also happen when the heart is stiff and does not fill normally.
sST2 is not usually ordered alone in a first evaluation. A typical workup may include physical exam, blood pressure, oxygen level, ECG, chest imaging, kidney function, electrolytes, liver markers, natriuretic peptides, troponin when acute heart injury is possible, and an echocardiogram.
Preparation is usually simple. Most people do not need to fast. A blood sample is drawn from a vein, and the result is reported in ng/mL by many laboratories. The exact turnaround time depends on whether the test is run in-house or sent to a reference laboratory.
Before testing, tell the clinician about recent infection, inflammatory disease flares, major surgery, trauma, kidney disease, lung disease, cancer treatment, and current heart medications. These details help place the result in context.
Normal Range, High sST2, and Result Patterns
Many laboratories and clinical studies use 35 ng/mL as a practical cut point for sST2 risk interpretation. A result at or below 35 ng/mL is generally considered lower risk in heart failure populations. A result above 35 ng/mL is generally associated with higher risk of adverse outcomes, especially hospitalization or death in people already diagnosed with heart failure.
This does not mean 36 ng/mL is a medical emergency or that 34 ng/mL is automatically safe. sST2 is a risk marker, not a yes-or-no diagnosis. The direction of change, the clinical setting, and other test results often matter more than a single borderline value.
| sST2 result pattern | Common interpretation | Usual next step |
|---|---|---|
| At or below 35 ng/mL | Lower risk pattern in many heart failure studies | Continue routine clinical monitoring if symptoms are stable |
| Above 35 ng/mL | Higher risk pattern, especially in known heart failure | Review symptoms, medications, volume status, BNP or NT-proBNP, kidney function, and imaging |
| Rising over time | May suggest worsening cardiac stress or remodeling risk | Assess for worsening heart failure, infection, inflammation, poor medication adherence, or new cardiac disease |
| Falling after treatment | May suggest improved risk profile or reduced biological stress | Continue clinician-guided treatment and follow-up |
Some laboratories may provide their own reference interval, assay-specific comments, or different interpretive language. Always compare the result with the reporting lab’s units and reference information. An sST2 result in ng/mL should not be casually compared with a result from another method unless the assays are known to align.
A very high result is more concerning when it appears together with worsening symptoms: breathlessness when lying flat, rapid weight gain, leg swelling, fatigue, reduced exercise tolerance, or repeated hospital visits. It also becomes more meaningful when BNP or NT-proBNP is high, troponin is elevated, kidney function is worsening, or an echocardiogram shows reduced pumping function, high filling pressures, or structural heart disease.
Low sST2 is usually not a disease marker. The test is mainly interpreted for elevated values and trends.
High sST2 and Heart Failure Risk
High sST2 is most useful as a prognosis marker in heart failure. Prognosis means the likely course of disease, including the chance of worsening symptoms, hospitalization, or death. In many studies, people with higher sST2 levels had worse outcomes than people with lower levels, even after accounting for other risk factors.
The reason is biological. Heart failure is not only about weak pumping. It also involves pressure overload, chamber stretch, inflammation, scarring, kidney-heart interactions, blood vessel changes, and neurohormonal activation. sST2 gives a window into the inflammation-and-remodeling part of that process.
A high sST2 level can suggest that the heart is under stress even when symptoms seem modest. For example, someone with chronic heart failure may feel “about the same,” but a rising sST2 level could prompt a clinician to look more closely at weight changes, blood pressure, medication doses, salt intake, rhythm problems, kidney function, and echocardiogram findings.
High sST2 does not identify the exact cause of heart failure. It cannot tell whether the cause is coronary artery disease, long-standing high blood pressure, valve disease, cardiomyopathy, myocarditis, atrial fibrillation, kidney disease, or another condition. It also cannot tell whether a person needs a specific drug. It is better understood as a risk signal that may sharpen the urgency and intensity of follow-up.
In chronic heart failure, serial testing can be more informative than one test. A falling sST2 after treatment may suggest improved biological stress. A persistently high or rising sST2 may suggest higher risk, incomplete response, ongoing inflammation, or progression. Still, treatment changes should be based on the whole clinical picture, not on the sST2 result alone.
High sST2 can also appear after acute cardiac events, including acute decompensated heart failure and myocardial infarction. In those situations, clinicians usually rely on immediate markers and imaging first, especially troponin, ECG, BNP or NT-proBNP, oxygen status, and echocardiography. sST2 may add longer-range risk information after the acute problem is recognized.
How sST2 Fits With BNP, NT-proBNP, Troponin, and Galectin-3
sST2 works best as part of a biomarker pattern. Each cardiac blood test answers a different question.
BNP and NT-proBNP are natriuretic peptides. They rise when the heart is stretched, often from increased pressure or volume. They are widely used to support the diagnosis of heart failure and to assess severity. A deeper discussion of these markers is covered in BNP and NT-proBNP interpretation.
sST2 does not replace them. Instead, it can add information because it reflects fibrosis, inflammation, and remodeling. This is why a high sST2 with a high NT-proBNP is often more concerning than either marker alone.
Troponin is different. It is a heart muscle injury marker. A high troponin can occur with a heart attack, myocarditis, severe heart failure, kidney disease, pulmonary embolism, sepsis, or other serious stress states. When symptoms suggest chest pain, pressure, fainting, or acute shortness of breath, troponin and ECG are urgent tools. sST2 should never delay emergency evaluation. For broader comparison, troponin and BNP patterns help separate heart injury signals from heart failure strain signals.
Galectin-3 is another fibrosis-related marker sometimes discussed in heart failure. Like sST2, it has been studied for prognosis and remodeling. Unlike BNP and NT-proBNP, neither sST2 nor galectin-3 is usually the first-line test for diagnosing heart failure in routine care. The galectin-3 blood test is more often considered when clinicians are looking at fibrosis and longer-term risk.
Kidney function also matters. BNP and NT-proBNP can be higher in people with reduced kidney function because clearance changes and heart-kidney stress often overlap. sST2 appears to be less affected by kidney function than natriuretic peptides, which can make it useful as an added risk marker. Still, kidney results such as creatinine and eGFR remain important because kidney disease can worsen heart failure and affect medication choices. The relationship between creatinine and eGFR is often reviewed when interpreting cardiac biomarkers.
| Marker | Main signal | Common clinical use |
|---|---|---|
| sST2 | Cardiac stress, inflammation, fibrosis, remodeling | Risk stratification in heart failure |
| BNP or NT-proBNP | Heart chamber stretch and pressure/volume overload | Diagnosing and assessing heart failure |
| Troponin I or T | Heart muscle injury | Evaluating possible heart attack or myocardial injury |
| Galectin-3 | Fibrosis and inflammation pathways | Selected risk assessment in heart failure |
A useful way to read these tests is to ask what pathway is active. High NT-proBNP suggests stretch. High troponin suggests injury. High sST2 suggests stress-remodeling biology. When several are abnormal at the same time, the person often needs closer evaluation.
Non-Heart Causes and Result Confounders
sST2 is strongly studied in heart failure, but it is not heart-specific in the way many people assume. It is involved in immune and inflammatory signaling, so levels can rise in conditions outside classic heart failure.
Possible contributors to higher sST2 include:
- Acute infection or systemic inflammation
- Severe lung disease or respiratory stress
- Kidney disease and heart-kidney stress
- Liver disease or advanced systemic illness
- Autoimmune or inflammatory disorders
- Major surgery, trauma, or critical illness
- Acute coronary syndrome, myocarditis, or other cardiac injury states
This is why a high result should not be translated into one diagnosis. A person with pneumonia, sepsis, or a major inflammatory flare may have an elevated sST2 because the body is under intense stress. A person with known heart failure and fluid overload may have a high result because cardiac remodeling pathways are active. The same number can mean different things in different settings.
Compared with BNP and NT-proBNP, sST2 seems less influenced by age, body mass index, atrial fibrillation, anemia, and kidney function. That is one reason researchers and cardiologists find it appealing. “Less influenced,” however, does not mean “unaffected by everything.” A biomarker can still be elevated because a person is severely ill, inflamed, or experiencing multiple organ stress.
Assay differences also matter. Different platforms may not produce perfectly interchangeable numbers. A result from one laboratory should be trended with the same laboratory method when possible. When the test is repeated, timing should also be considered. A value drawn during an acute hospitalization should not be compared too casually with a stable outpatient value months later.
Medication timing can also affect interpretation indirectly. sST2 may fall when heart failure becomes better controlled, but the test does not tell which medication caused the change. Diuretics, SGLT2 inhibitors, beta blockers, ACE inhibitors, ARBs, ARNIs, mineralocorticoid receptor antagonists, blood pressure control, rhythm management, device therapy, and valve treatment may all change the clinical picture.
What to Do After a High sST2 Result
A high sST2 result deserves context, not panic. The next step depends on symptoms, known heart disease, other blood tests, and whether the result is new, rising, or persistently elevated.
For a person with known heart failure, the clinician may review:
- Recent weight gain or swelling
- Shortness of breath during activity or when lying flat
- Nighttime breathlessness
- Blood pressure and heart rate trends
- Medication doses and missed doses
- Salt intake, alcohol intake, and fluid intake
- Kidney function, potassium, sodium, and liver markers
- BNP or NT-proBNP trend
- Troponin if acute injury is possible
- Echocardiogram results and ejection fraction
- Heart rhythm, especially atrial fibrillation or frequent ectopy
A high result may lead to closer follow-up, medication optimization, repeat biomarkers, an echocardiogram, rhythm monitoring, or referral to a cardiologist or heart failure specialist. It may also prompt a search for triggers such as infection, uncontrolled blood pressure, medication side effects, anemia, thyroid disease, kidney decline, excess salt intake, or a new ischemic event.
For a person without known heart failure, a high sST2 should not automatically be treated as heart failure. The clinician may first ask whether symptoms fit. Shortness of breath, reduced exercise tolerance, swelling, unexplained fatigue, chest discomfort, or rapid weight gain may justify a broader cardiac evaluation. Without symptoms, the result may be repeated or interpreted alongside risk factors such as high blood pressure, diabetes, kidney disease, coronary artery disease, sleep apnea, and obesity.
Urgent care is needed when symptoms suggest an acute problem. Seek emergency help for chest pain or pressure, severe shortness of breath, fainting, new confusion, coughing pink frothy sputum, blue lips, oxygen levels that are low, sudden one-sided weakness, or rapidly worsening swelling with breathlessness. In those moments, emergency evaluation matters more than any outpatient biomarker result.
For people tracking sST2 over time, consistency helps. Try to use the same lab, similar timing, and a planned interval chosen by the clinician. A single test can be informative, but a trend often gives a clearer picture.
Limits of the Test and Common Misunderstandings
sST2 has useful prognostic value, but it has limits. The most common mistake is treating it like a stand-alone diagnosis. A high sST2 does not prove heart failure. A normal sST2 does not rule out heart failure. The test provides risk information, mainly in people who already have heart failure or a strong reason to suspect cardiac stress.
Another misunderstanding is assuming sST2 identifies a heart attack. It does not. A person with chest pain, pressure, sweating, nausea, shortness of breath, or pain spreading to the arm, jaw, back, or neck needs urgent evaluation with ECG and troponin-based protocols. sST2 may add prognostic information later, but it is not the main emergency rule-out marker.
A third misunderstanding is assuming 35 ng/mL is a universal healthy-versus-sick boundary. It is better viewed as a commonly used prognostic cut point. Borderline results need clinical judgment. A result of 38 ng/mL in a stable person is different from 90 ng/mL in someone hospitalized with worsening heart failure and rising NT-proBNP.
sST2 also does not replace imaging. An echocardiogram can show ejection fraction, valve disease, chamber size, wall thickness, pulmonary pressures, and filling patterns. Blood tests can suggest risk, but imaging shows structure and function.
The test is also not yet used uniformly across clinics. BNP, NT-proBNP, troponin, creatinine, electrolytes, ECG, and echocardiography are far more standard in routine care. sST2 is more often used in specialty settings, advanced risk stratification, or situations where clinicians want an additional view of remodeling biology.
A helpful interpretation asks four questions:
- Does the person have symptoms or known heart failure?
- Is sST2 above the lab’s risk cut point or rising over time?
- Do BNP, NT-proBNP, troponin, kidney function, ECG, or echocardiogram results support cardiac stress?
- Is there another active illness, such as infection or inflammation, that could raise sST2?
When those questions are answered together, sST2 becomes more useful and less confusing.
References
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure 2022 (Guideline)
- Soluble ST2 in Heart Failure: A Clinical Role beyond B-Type Natriuretic Peptide 2023 (Review)
- Prognostic Value of sST2 in Heart Failure 2023 (Review)
- The Diagnostic Value of Soluble ST2 in Heart Failure: A Meta-Analysis 2021 (Systematic Review)
- Performance Evaluation of AFIAS ST2 and Ichroma ST2 Assays in Comparison with Presage ST2 Assay 2023 (Method Comparison)
- Serum Soluble ST2 Is a Valuable Prognostic Biomarker in Patients With Acute Heart Failure 2022 (Cohort Study)
Disclaimer
sST2 results should be interpreted by a qualified clinician who can review symptoms, exam findings, medications, imaging, and other blood tests. A high sST2 result can signal increased risk, but it does not diagnose heart failure, heart attack, or any single condition by itself. Seek urgent medical care for chest pain, severe shortness of breath, fainting, confusion, or rapidly worsening swelling.
